The FTC’s second request imposes an additional waiting period of up to 30 days for the agency to review the deal from the time the Novo Nordisk Foundation and Catalent submit the required information.
During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the ...
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several ...
ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, ...
It’s been a turbulent few days for GSK’s respiratory business: On Tuesday, the U.S. Federal Trade Commission (FTC) further cracked down on “junk patent listings,” including those related to a quartet ...
Japan's Ono Pharmaceutical will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in radiopharmaceuticals with two deals. WuXi Biologics has withdrawn from the 2024 BIO ...
Eli Lilly has a Fever, and the only prescription is a new corporate partnership. | Eli Lilly has a Fever, and the only ...
Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...
Preeclampsia, a pregnancy complication typically associated with high blood pressure, is estimated to affect around one in ...
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...
As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...
Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat chronic obstructive pulmonary disease (COPD) could be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results